{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:53:58Z","timestamp":1742403238067},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,8]]},"DOI":"10.7759\/cureus.16266","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T19:01:35Z","timestamp":1625770895000},"source":"Crossref","is-referenced-by-count":4,"title":["Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer"],"prefix":"10.7759","author":[{"given":"Angel R","family":"Baroz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa","family":"Mambetsariev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Pharaon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TingTing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trilokesh","family":"Kidambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karamjeet S","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Koczywas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq630","article-title":"Identifying cancer driver genes in tumor genome sequencing studies","volume":"27","author":"Youn A","year":"2011","unstructured":"Youn A, Simon R. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics. 2011, 27:175-81. 10.1093\/bioinformatics\/btq630","journal-title":"Bioinformatics"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21288","article-title":"Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma","volume":"121","author":"Cai G","year":"2013","unstructured":"Cai G, Wong R, Chhieng D, et al.. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol. 2013, 121:500-7. 10.1002\/cncy.21288","journal-title":"Cancer Cytopathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-016-2000-3","article-title":"Testing for ROS1 in non-small cell lung cancer: a review with recommendations","volume":"469","author":"Bubendorf L","year":"2016","unstructured":"Bubendorf L, B\u00fcttner R, Al-Dayel F, et al.. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016, 469:489-503. 10.1007\/s00428-016-2000-3","journal-title":"Virchows Arch"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan M","year":"2019","unstructured":"Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019, 4:61. 10.1038\/s41392-019-0099-9","journal-title":"Signal Transduct Target Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051362","article-title":"Immune checkpoint inhibitors for lung cancer treatment: a review","volume":"9","author":"Onoi K","year":"2020","unstructured":"Onoi K, Chihara Y, Uchino J, et al.. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med. 2020, 9:1362. 10.3390\/jcm9051362","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-017-0308-6","article-title":"PD-L1 testing in guiding patient selection for PD-1\/PD-L1 inhibitor therapy in lung cancer","volume":"22","author":"Ancevski Hunter K","year":"2018","unstructured":"Ancevski Hunter K, Socinski MA, Villaruz LC. PD-L1 testing in guiding patient selection for PD-1\/PD-L1 inhibitor therapy in lung cancer. Mol Diagn Ther. 2018, 22:1-10. 10.1007\/s40291-017-0308-6","journal-title":"Mol Diagn Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"38","author":"Hanna NH","year":"2020","unstructured":"Hanna NH, Schneider BJ, Temin S, et al.. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2020, 38:1608-32. 10.1200\/JCO.19.03022","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TS","year":"2019","unstructured":"Mok TS, Wu YL, Kudaba I, et al.. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019, 393:1819-30. 10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone DP","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, et al.. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017, 376:2415-26. 10.1056\/NEJMoa1613493","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready N","year":"2019","unstructured":"Ready N, Hellmann MD, Awad MM, et al.. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol. 2019, 37:992-1000. 10.1200\/JCO.18.01042","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst RS","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, et al.. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020, 383:1328-39. 10.1056\/NEJMoa1917346","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares L","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al.. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018, 379:2040-51. 10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski MA","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, et al.. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018, 378:2288-301. 10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares L","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, et al.. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:198-211. 10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar B","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR, et al.. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020, 6:1952-6. 10.1001\/jamaoncol.2020.5012","journal-title":"JAMA Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy N","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, et al.. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019, 6:e48-57. 10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1722022","article-title":"Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database","volume":"9","author":"Scanvion Q","year":"2020","unstructured":"Scanvion Q, B\u00e9n\u00e9 J, Gautier S, et al.. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. Oncoimmunology. 2020, 9:1722022. 10.1080\/2162402X.2020.1722022","journal-title":"Oncoimmunology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000380","article-title":"A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab","volume":"8","author":"Olson DJ","year":"2020","unstructured":"Olson DJ, Rajagopal P, Tjota MY, Venkataraman G, Luke JJ, Gajewski TF. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. J Immunother Cancer. 2020, 8:e000380. 10.1136\/jitc-2019-000380","journal-title":"J Immunother Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis EJ","year":"2019","unstructured":"Davis EJ, Salem JE, Young A, et al.. Hematologic complications of immune checkpoint inhibitors. Oncologist. 2019, 24:584-8. 10.1634\/theoncologist.2018-0574","journal-title":"Oncologist"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey MS","year":"2020","unstructured":"Dickey MS, Raina AJ, Gilbar PJ, Wisniowski BL, Collins JT, Karki B, Nguyen AD. Pembrolizumab-induced thrombotic thrombocytopenic purpura. J Oncol Pharm Pract. 2020, 26:1237-40. 10.1177\/1078155219887212","journal-title":"J Oncol Pharm Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.104","article-title":"Peritumoral eosinophils predict recurrence in colorectal cancer","volume":"28","author":"Harbaum L","year":"2015","unstructured":"Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Bokemeyer C, Langner C. Peritumoral eosinophils predict recurrence in colorectal cancer. Mod Pathol. 2015, 28:403-13. 10.1038\/modpathol.2014.104","journal-title":"Mod Pathol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X10392443","article-title":"Eosinophilic colitis: epidemiology, clinical features, and current management","volume":"4","author":"Alfadda AA","year":"2011","unstructured":"Alfadda AA, Storr MA, Shaffer EA. Eosinophilic colitis: epidemiology, clinical features, and current management. Therap Adv Gastroenterol. 2011, 4:301-9. 10.1177\/1756283X10392443","journal-title":"Therap Adv Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0223-RA","article-title":"Blood and bone marrow evaluation for eosinophilia","volume":"140","author":"Boyer DF","year":"2016","unstructured":"Boyer DF. Blood and bone marrow evaluation for eosinophilia. Arch Pathol Lab Med. 2016, 140:1060-7. 10.5858\/arpa.2016-0223-RA","journal-title":"Arch Pathol Lab Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/63565-elevated-eosinophil-count-following-pembrolizumab-treatment-for-non-small-cell-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:46Z","timestamp":1707506806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/63565-elevated-eosinophil-count-following-pembrolizumab-treatment-for-non-small-cell-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.16266","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}